ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 6.270-6.620 for the period, compared to the consensus estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several recent analyst reports. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st. Guggenheim reissued a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $66.28 on Friday. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $77.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business has a 50 day simple moving average of $66.86 and a 200-day simple moving average of $60.69. The firm has a market capitalization of $1.44 billion, a PE ratio of -120.51 and a beta of 0.56.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analysts’ expectations of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s quarterly revenue was up 43.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.82 earnings per share. Equities research analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock worth $197,792. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.